Revisi per 10 November 2024 06.29 sunting Muhammad Anas Sidik (bicara \| kontrib) 24.365 suntingan Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan ← Revisi sebelumnya		Revisi terkini sejak 10 November 2024 06.30 sunting balikkan Muhammad Anas Sidik (bicara \| kontrib) 24.365 suntingan Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan
Baris 137: ===Kanada=== ''Health Canada'' menyetujui Jubbonti, biosimilar untuk Prolia, pada bulan Februari 2024;<ref name="Jubbonti CA">{{cite web \| title=Regulatory Decision Summary for Jubbonti \| website=Drug and Health Products Portal \| date=16 February 2024 \| url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1710165579186 \| access-date=1 April 2024 \| archive-date=1 April 2024 \| archive-url=https://web.archive.org/web/20240401064821/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1710165579186 \| url-status=live }}</ref> dan menyetujui Wyost, biosimilar untuk Xgeva, pada bulan Maret 2024.<ref name="Wyost CA">{{cite web \| title=Regulatory Decision Summary for Wyost \| website=Drug and Health Products Portal \| date=1 March 2024 \| url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1710769045419 \| access-date=1 April 2024 \| archive-date=1 April 2024 \| archive-url=https://web.archive.org/web/20240401064821/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1710769045419 \| url-status=live }}</ref> ==Referensi==

Denosumab: Perbedaan antara revisi